Loss of the tumor suppressor RB is an established mechanism of de novo and acquired resistance to CDK4/6i, and with the wider use of these agents as standard treatment, the population of patients with RB-deficient breast tumors is likely to rapidly increase. Here, CDK4 is linked to breast neoplasm.